Access the full text.
Sign up today, get DeepDyve free for 14 days.
rosiglitazone Investigators, H. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, J. Shaw, B. Zinman, R. Holman (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 368
M. Molitch (2003)
Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.Diabetes care, 26 4
W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, Elizabeth Walker, David Nathan (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.The New England journal of medicine, 346 6
J. Chiasson, R. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso (2002)
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialThe Lancet, 359
(2007)
How) can we prevent type 2 diabetes? Diabetes 2007;56:1502–1507
T. Buchanan, A. Xiang, R. Peters, S. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. Hodis, S. Azen (2002)
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.Diabetes, 51 9
A. Brett (2001)
Can We Prevent Type 2 DiabetesNEJM Journal Watch, 2001
T. Buchanan (2007)
(How) Can We Prevent Type 2 Diabetes?Diabetes, 56
J. Tuomilehto, J. Lindström, J. Eriksson, T. Valle, H. Hämäläinen, P. Ilanne-Parikka, S. Keinänen-Kiukaanniemi, M. Laakso, A. Louheranta, M. Rastas, V. Salminen, S. Aunola, Z. Cepaitis, V. Moltchanov, M. Hakumäki, M. Mannelin, V. Martikkala, J. Sundvall, M. Uusitupa (2001)
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.The New England journal of medicine, 344 18
A tidal wave of “prediabetes” and, right behind it, an epidemic of type 2 diabetes are sweeping through developed countries and threatening to do the same in developing countries. Credible estimates suggest that if nothing is done to stem the tide of hyperglycemia, the number of people with diabetes worldwide will be around half a billion within the next 20 years. And stemming that tide will require effective, long‐term methods to preserve or restore pancreatic β‐cell compensation for insulin resistance. I believe that we will need to go beyond lifestyle changes and medications if we are to win this important battle. Here's why. Over the past decade, we have learned from clinical trials that we can reduce the risk of type 2 diabetes in high‐risk individuals by subjecting them to lifestyle changes or medications that reduce obesity, insulin resistance, and glucose levels. These findings have led to some very hopeful public messages along the lines of “Losing a small amount of weight will prevent or delay diabetes.” Although this statement is technically true, I am concerned that it vastly underestimates the power of the enemy—obesity—to damage the pancreatic β‐cells. We must protect these cells if we are to
Obesity – Wiley
Published: Jun 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.